Search

Your search keyword '"Keating, Claire"' showing total 12 results
Start Over Author "Keating, Claire" Publication Type Magazines
12 results on '"Keating, Claire"'

1. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

Author

Uluer, Ahmet Z, MacGregor, Gordon, Azevedo, Pilar, Indihar, Veronica, Keating, Claire, Mall, Marcus A, McKone, Edward F, Ramsey, Bonnie W, Rowe, Steven M, Rubenstein, Ronald C, Taylor-Cousar, Jennifer L, Tullis, Elizabeth, Yonker, Lael M, Chu, Chenghao, Lam, Anna P, Nair, Nitin, Sosnay, Patrick R, Tian, Simon, Van Goor, Fredrick, Viswanathan, Lakshmi, Waltz, David, Wang, Linda T, Xi, Yingmei, Billings, Joanne, Horsley, Alexander, Horsley, Alexander, Nash, Edward F., Bakker, Marleen, van der Meer, Renske, Merkus, Petrus, Majoor, Christof, McCoy, Karen, Billings, Joanne, Pancham, Krishna, Tolle, James, Quick, Bryon, Uluer, Ahmet, DiMango, Emily, Rao, Adupa, Reyes, Santiago, Klingsberg, Ross, Barreto, Celeste, Ortega, Victor, Willey-Courand, Donna, Schwarz, Carsten, Sutharsan, Sivagurunathan, Fischer, Rainald, Davies, Jane, Duckers, Jamie, Horsley, Alexander, Doe, Simon, Nash, Edward F., Bakker, Marleen, Heijerman, Harry, van der Meer, Renske, Merkus, Petrus, Majoor, Christof, Solomon, George M., Merlo, Christian, Griffonnet, Jennifer, Pilewski, Joseph, Dunitz, Jordan, Sheikh, Saba, Rubenstein, Ronald C., Rosenbluth, Daniel B., Liou, Theodore, Indihar, Maria, Pancham, Krishna, Yonker, Lael, Nasr, Samya, Griffonnet, Jennifer, Brown, Cynthia D., Sawicki, Gregory S., Ruddy, Jennifer, DiMango, Emily, Garcia, Bryan, Braun, Andrew, Gifford, Alex H., Mehdi, Nighat, Tupayachi Ortiz, Maria, Jain, Raksha, Calimano, Francisco J., Johannes, Jimmy, Daines, Cori L., Fullmer, Jason, Mermis, Joel, Barrios, Christopher, Ly, Ngoc, Casserly, Brian P., Eisenmann, Stephan, Hebestreit, Helge, Kiefer, Alexander, Sutharsan, Sivagurunathan, Fischer, Rainald, MacGregor, Gordon, Peckham, Daniel, Ledson, Martin, Van Braeckel, Eva, Merkus, Petrus, McElvaney, Noel Gerard, McKone, Edward, Plant, Barry, Burr, Lucy, Smith, Daniel J., Middleton, Peter, and Wilson, John

Abstract

Elexacaftor–tezacaftor–ivacaftor has been shown to be safe and efficacious in people with cystic fibrosis and at least one F508delallele. Our aim was to identify a novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination capable of further increasing CFTR-mediated chloride transport, with the potential for once-daily dosing.

Published
2023
Full Text
View/download PDF

2. Implementation of an outpatient clinical pharmacy service at an adult cystic fibrosis center

Author

Marshall, Olga, Dous, Engy, Simpson, Kaitlyn, Leu, Cheng-Shiun, Han, Jiying, Keating, Claire, and DiMango, Emily

Abstract

High treatment burden can adversely impact health outcomes in people with cystic fibrosis (PwCF). There is a continued need for medication adherence education and further research to evaluate impact of cystic fibrosis (CF) pharmacist interventions in an ambulatory care setting.

Published
2025
Full Text
View/download PDF

4. Association of Quality of Life Measures and Otolaryngologic Care in Cystic Fibrosis Patients

Author

Leong, Stephen, Sharma, Rahul K., Safi, Chetan, DiMango, Emily, Keating, Claire, Gudis, David A., and Overdevest, Jonathan B.

Abstract

Objectives: Appropriate management of chronic rhinosinusitis (CRS) among patients with cystic fibrosis (CF) is important in improving quality of life. Otolaryngologists play a critical role in reducing CRS symptom burden. This study seeks to evaluate the role of patient-reported quality-of-life measures in guiding interventions for CF-related sinus disease.Methods: We performed a prospective, cross-sectional study of 105 patients presenting to a CF-accredited clinic between July and September 2018. Demographic data and sinus surgery history were collected, in addition to Sino-Nasal Outcome Test (SNOT-22) and Questionnaire of Olfactory Disorders (QOD-NS) scores. Statistical analysis was conducted using correlation and non-parametric Mann-Whitney Utests.Results: Baseline well-care visits accounted for 71.4% of all clinical evaluations. Prior otolaryngology intervention was noted in 69 (66%) patients, where the majority of these patients (63/69; 91%) underwent endoscopic sinus surgery (ESS). Patients with a history of otolaryngology intervention had an average SNOT-22 score of 33.2 (SD = 20.6) compared to 24.9 (SD = 18.5) for patients without prior intervention (P= .048). The average QOD-NS score was 5.5 (SD = 6.4) among patients referred to otolaryngologists and 3.1 (SD = 5.7) for non-referred patients (P= .012). SNOT-22 and QOD-NS scores were modestly correlated (Rof .43).Conclusion: CF patients with symptoms resulting in worse quality-of-life assessments were more likely to have established coordinated care with an otolaryngologist. Further validation of the utility of SNOT-22 and QOD-NS questionnaires as care coordination metrics is necessary in the CF population.

Published
2022
Full Text
View/download PDF

5. Pseudomonas aeruginosaSusceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation

Author

Keating, Claire L., Zuckerman, Jonathan B., Singh, Pradeep K., McKevitt, Matthew, Gurtovaya, Oksana, Bresnik, Mark, Marshall, Bruce C., and Saiman, Lisa

Abstract

The approval of aztreonam lysine for inhalation solution (AZLI) raised concerns that additional antibiotic exposure would potentially affect the susceptibility profiles of Pseudomonas aeruginosaisolates from cystic fibrosis (CF) patients. This 5-year, prospective, observational study tracked susceptibility changes and clinical outcomes in CF patients in the United States with chronic P. aeruginosainfection.

Published
2021
Full Text
View/download PDF

6. Laryngeal Injury Due to Amikacin Inhalation for Refractory Mycobacterium aviumComplex Infection

Author

Axiotakis, Lucas G., Enver, Necati, Keating, Claire L., and Pitman, Michael J.

Abstract

Inhaled antibiotics have long been used for chronic lung infections, especially in patients with cystic fibrosis and increasingly for non-cystic fibrosis bronchiectasis. Amikacin liposome inhalation suspension (ALIS) has emerged as a promising treatment for Mycobacterium aviumcomplex infection refractory to oral antibiotics. However, despite its efficacy, nearly one-half of patients in phase II and III trials experienced dysphonia as a treatment-associated adverse effect. Here, we describe a patient who experienced severe, acute-onset laryngitis while receiving ALIS for refractory M aviumcomplex infection, prompting discontinuation of ALIS therapy. This is the first report directly describing vocal fold injury due to such therapy. Given the high frequency of dysphonia reported with ALIS, this case highlights the potential severity of laryngeal toxicity, the importance of coordination of care for patients receiving inhaled antibiotics for chronic pulmonary disease, and the need for better insight into mechanisms of toxicity.

Published
2021
Full Text
View/download PDF

7. THE CLINICAL IMPACT OF COVID-19 ON CYSTIC FIBROSIS PATIENTS IN NEW YORK

Author

SIMONSON, JOSEPH, ESPOSITO, CHRISTINE, FRANTZEN, THERESA, HENTHORNE, KATHERINE, RAMDEO, RAMONA, TRENTACOSTE, JESSICA, TSANG, DONNA, LA VECCHIA, GERALYN, ABDULLAH, ROBERT, BERDELLA, MARIA, BONITZ, LYNN, CONDOS, RANY, CONSTANTINESCU, ANDREI, DECELIE- GERMANA, JOAN, DI MANGO, EMILY, GIUSTI, ROBERT, KEATING, CLAIRE, KIER, CATHERINE, LENNOX, ALISON, SADEGHI, HOSSEIN, WALKER, PATRICIA, and WANG, JANICE

Published
2021
Full Text
View/download PDF

8. Response

Author

Axiotakis, Lucas G., Enver, Necati, Keating, Claire L., and Pitman, Michael J.

Published
2021
Full Text
View/download PDF

9. Thesis Abstracts

Author

Marie Beck, Elyse, Brindley, Jared, Dawson, Frances, Fleming, Kelly, Foley, Elizabeth, Garnaut, Julia, Greaves, Amanda, Harris, Matthew, Keating, Claire, Lavers, Jane, Moult, Lily, Nichols, Stephen, O’Donohue, Peter, Petruzzelli, Bianca, Piotrowski, Silas, Rodrigues, Jennifer, Spiers, Oliver, Stephenson, Birgitta, Tedman, Samantha, Walker, Jesse, and Wilson, Wilson

Published
2012
Full Text
View/download PDF

10. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation

Author

Narayanasami, Uma, Kanteti, Rajani, Morelli, Julie, Klekar, Alanna, Al-Olama, Asma, Keating, Claire, O'Connor, Colleen, Berkman, Eugene, Erban, John K., Sprague, Kellie A., Miller, Kenneth B., and Schenkein, David P.

Abstract

Peripheral blood cell (PBC) rescue has become the mainstay for autologous transplantation in patients with lymphoma, multiple myeloma, and solid tumors. Different methods of hematopoietic progenitor cell (HPC) mobilization are in use without an established standard. Forty-seven patients with relapsed or refractory lymphoma received salvage chemotherapy and were randomized to have HPC mobilization using filgrastim [granulocyte–colony-stimulating factor (G-CSF)] alone for 4 days at 10 μg/kg per day (arm A) or cyclophosphamide (5 g/m2) and G-CSF at 10 μg/kg per day until hematologic recovery (arm B). Engraftment and ease of PBC collection were primary outcomes. All patients underwent the same high-dose chemotherapy followed by reinfusion of PBCs. There were no differences in median time to neutrophil engraftment (11 days in both arms;P = .5) or platelet engraftment (14 days in arm A, 13 days in arm B; P = .35). Combined chemotherapy and G-CSF resulted in higher CD34+ cell collection than G-CSF alone (median, 7.2 vs 2.5 × 106 cells/kg;P = .004), but this did not impact engraftment. No differences were found in other PBC harvest outcomes or resource utilization measures. A high degree of tumor contamination, as studied by consensus CDR3 polymerase chain reaction of the mobilized PBCs, was present in both arms (92% in arm A vs 90% in arm B;P = 1). No differences were found in overall survival or progression-free survival at a median follow-up of 21 months. This randomized trial provides clinical evidence that the use of G-CSF alone is adequate for HPC mobilization, even in heavily pretreated patients with relapsed lymphoma.

Published
2001
Full Text
View/download PDF

11. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR(EXTEND): an open-label extension study

Author

Flume, Patrick A, Biner, Reta Fischer, Downey, Damian G, Brown, Cynthia, Jain, Manu, Fischer, Rainald, De Boeck, Kris, Sawicki, Gregory S, Chang, Philip, Paz-Diaz, Hildegarde, Rubin, Jaime L, Yang, Yoojung, Hu, Xingdi, Pasta, David J, Millar, Stefanie J, Campbell, Daniel, Wang, Xin, Ahluwalia, Neil, Owen, Caroline A, Wainwright, Claire E, Gibson, Ronald L., Rowe, Steven M., Lechtzin, Noah, Ahrens, Richard C., McCoy, Karen S., Aitken, Moira, Donaldson, Scott H., McBennett, Kimberly Ann, Pilewski, Joseph M., Billings, Joanne, Milla, Carlos, Rubenstein, Ronald, Rosenbluth, Daniel Brian, Linnemann, Rachel, Powers, Michael R., Fortner, Christopher, Frederick, Carla Anne, Liou, Theodore G., Black, Philip, Wang, Janice, Colombo, John L., Berdella, Maria, Indihar, Maria Veronica, Brown, Cynthia D., Anstead, Michael, Bilodeau, Lara, Sicilian, Leonard, Jain, Manu, Tolle, James Jerome, Moffett, Kathryn, Nasr, Samya, Taylor-Cousar, Jennifer, Barto, Tara Lynn, Antos, Nicholas, Rogers, John S., Quick, Bryon, Thompson, Henry R., Sawicki, Gregory, Barnett, Bruce, Zanni, Robert L., Smith, Thomas C., Schultz, Karen D., Keating, Claire, Flume, Patrick, Omlor, Gregory J., Ashare, Alix, Voter, Karen, Mehdi, Nighat, Ortiz, Maria Gabriela Tupayachi, Gardner, Tonia E., Boas, Steven R., Messore, Barbara, Zemanick, Edith, Jain, Raksha, McCarthy, Michael, Kissner, Dana G., Patel, Kapilkumar, McNamara, John, Philley, Julie, Berlinski, Ariel, Calimano, Francisco J., Chin, Terry, Conrad, Douglas, Daines, Cori, Raissy, Hengameh H., Keens, Thomas G., Lascano, Jorge E., McWilliams, Bennie, Morrissey, Brian, Reyes, Santiago, Chittivelu, Subramanyam, Hussain, Sabiha, Stone, Arvey, Wallace, James, Klingsberg, Ross, Biller, Julie A., Bui, Stephanie, Sommerburg, Olaf, Bignamini, Elisabetta, Collura, Mirella, Biner, Reta Fischer, Moller, Alexander, Salvatore, Donatello, Belleguic, Chantal, Bentur, Lea, Efrati, Ori, Kerem, Eitan, Prais, Dario, Gallego, Esther Quintana, Barry, Peter, Livnat-Levanon, Galit, Asensi, Jose Ramon Villa, Armstrong, David Stuart, de la Cruz, Oscar Asensio, Gilchrist, Francis, Tullis, Diana Elizabeth, Quon, Bradley, Lands, Larry C., Morrison, Nancy, Lavoie, Annick, Linnane, Barry, Elidemir, Okan, Ringshausen, Felix, Kappler, Matthias, Hebestreit, Helge, Mainz, Jochen, Kiefer, Alexander, Koerner-Rettberg, Cordula, Staab, Doris, Gleiber, Wolfgang, Pressler, Tacjana, Stehling, Florian, Hector, Andreas, Sutharsan, Sivagurunathan, Naehrlich, Lutz, Fischer, Rainald, Downey, Damian, Davies, Jane Carolyn, Ketchell, Robert Ian, Carroll, Mary Patricia, Doe, Simon, MacGregor, Gordon, Nash, Edward Fairbairn, Withers, Nicholas, Peckham, Daniel Gavin, Ledson, Martin James, Kansra, Sonal, Lee, Timothy William Rayner, Delaisi, Bertrand, Rault, Gilles, Le Bihan, Jean, Hubert, Dominique, Fajac, Isabelle, Sermet-Gaudelus, Isabelle, Bakker, Marleen, Arets, Bert, De Boeck, Christiane, Chiron, Raphael, Reix, Philippe, Mainguy, Catherine, van Braeckel, Eva, Malfroot, Anne, Durieu, Isabelle, Dufeu, Nadine Desmazes, Prevotat, Anne, van der Meer, Renske, Merkus, Petrus, Weersink, E.J.M., Gomez-Aguero, Isabel Barrio, Gartner, Silvia, Jover, Amparo Sole, Fernandez, Antonio Alvarez, Cox, Desmond William, McKone, Edward F., Plant, Barry James, Selvadurai, Hiranjan, Bowler, Simon David, Wainwright, Claire Elizabeth, Smith, Daniel, Middleton, Peter Gordon, Wilson, John William, Volpi, Sonia, Colombo, Carla, Fabrizzi, Benedetta, Lucidi, Vincenzina, Cresta, Federico, Cucchiara, Salvatore, Eber, Ernst, Ellemunter, Helmut, Huttegger, Isidor, Hjelte, Lena, Krantz, Christina, and Gilljam, Marita

Abstract

Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated over 8–24 weeks in phase 3 clinical studies in participants aged 12 years or older with cystic fibrosis homozygous for the Phe508del CFTRmutation (F/F; study 661-106 [EVOLVE]) or heterozygous for the Phe508del CFTRmutation and a residual function mutation (F/RF; study 661-108 [EXPAND]). Longer-term (>24 weeks) safety and efficacy of tezacaftor–ivacaftor has not been assessed in clinical studies. Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability, and efficacy of tezacaftor–ivacaftor in participants aged 12 years or older with cystic fibrosis who were homozygous or heterozygous for the Phe508del CFTRmutation.

Published
2021
Full Text
View/download PDF

12. Individualized Household Allergen Intervention Lowers Allergen Level But Not Asthma Medication Use: A Randomized Controlled Trial

Author

DiMango, Emily, Serebrisky, Denise, Narula, Surinder, Shim, Chang, Keating, Claire, Sheares, Beverly, Perzanowski, Matthew, Miller, Rachel, DiMango, Angela, Andrews, Howard, Merle, David, Liu, Xinhua, Calatroni, Agustin, and Kattan, Meyer

Abstract

Environmental exposures to indoor allergens are major contributors to asthma symptoms, particularly in inner cities. The effectiveness of household allergen reduction as an adjunct to National Asthma Education Prevention Program guideline–based pharmacologic therapy in asthma has not been prospectively studied.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results